Assessment of the Hospital Anxiety and Depression Scale for cancer patients

Assessment of the Hospital Anxiety and Depression Scale for cancer patients

Background: Depression and anxiety are common in patients with cancer. Aim: To adapt and validate the Hospital Anxiety and Depression Scale (HADS) for adult Chilean cancer patients, and to provide information about their prevalence of anxiety and depression. Material and Methods: Two hundred fift...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Villoria,Erica, Lara,Laura
Lenguaje:English
Publicado: Sociedad Médica de Santiago 2018
Materias:
Anxiety
Depression
Cancer
Psychometrics
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300300
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872018000300300
record_format dspace
spelling oai:scielo:S0034-988720180003003002018-06-20Assessment of the Hospital Anxiety and Depression Scale for cancer patientsVilloria,EricaLara,Laura Anxiety Depression Cancer Psychometrics Background: Depression and anxiety are common in patients with cancer. Aim: To adapt and validate the Hospital Anxiety and Depression Scale (HADS) for adult Chilean cancer patients, and to provide information about their prevalence of anxiety and depression. Material and Methods: Two hundred fifteen patients with cancer answered an adapted version of HADS for Chilean population. The language adjustment of the scale was carried out with the opinions of 10 expert linguists and with a pilot study on 17 cancer patients. The Depression and Anxiety subscales of the DASS-21 were also applied to verify the convergent validity of HADS: Results: The confirmatory factor analysis indicated that the data fits the model of two correlated factors (anxiety and depression), &#967;2 = 98.608; df = 76;p < 0.05; &#967;2/df= 1.23, RMSEA = 0.037; CFI = 0.99; TLI = .98. Reliability analysis showed an adequate internal consistency of both subscales (.76 for anxiety and .84 for depression) and the general scale (.87). Correlations between HADS and DASS-21 scores were significant for both anxiety (r =.514, p < 0.001) and depression (r = 0.600, p < 0.001). Prevalence rates were approximately 30% for depression (actual = 12%, possible = 22.8%) and approximately 20% for anxiety (actual = 7%, possible = 8.4%). Conclusions: We conclude that HADS is a reliable and valid instrument for screening clinically relevant anxiety and depression symptoms in Chilean cancer patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.3 20182018-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300300en10.4067/s0034-98872018000300300
institution Scielo Chile
collection Scielo Chile
language English
topic Anxiety
Depression
Cancer
Psychometrics
spellingShingle Anxiety
Depression
Cancer
Psychometrics
Villoria,Erica
Lara,Laura
Assessment of the Hospital Anxiety and Depression Scale for cancer patients
description Background: Depression and anxiety are common in patients with cancer. Aim: To adapt and validate the Hospital Anxiety and Depression Scale (HADS) for adult Chilean cancer patients, and to provide information about their prevalence of anxiety and depression. Material and Methods: Two hundred fifteen patients with cancer answered an adapted version of HADS for Chilean population. The language adjustment of the scale was carried out with the opinions of 10 expert linguists and with a pilot study on 17 cancer patients. The Depression and Anxiety subscales of the DASS-21 were also applied to verify the convergent validity of HADS: Results: The confirmatory factor analysis indicated that the data fits the model of two correlated factors (anxiety and depression), &#967;2 = 98.608; df = 76;p < 0.05; &#967;2/df= 1.23, RMSEA = 0.037; CFI = 0.99; TLI = .98. Reliability analysis showed an adequate internal consistency of both subscales (.76 for anxiety and .84 for depression) and the general scale (.87). Correlations between HADS and DASS-21 scores were significant for both anxiety (r =.514, p < 0.001) and depression (r = 0.600, p < 0.001). Prevalence rates were approximately 30% for depression (actual = 12%, possible = 22.8%) and approximately 20% for anxiety (actual = 7%, possible = 8.4%). Conclusions: We conclude that HADS is a reliable and valid instrument for screening clinically relevant anxiety and depression symptoms in Chilean cancer patients.
author Villoria,Erica
Lara,Laura
author_facet Villoria,Erica
Lara,Laura
author_sort Villoria,Erica
title Assessment of the Hospital Anxiety and Depression Scale for cancer patients
title_short Assessment of the Hospital Anxiety and Depression Scale for cancer patients
title_full Assessment of the Hospital Anxiety and Depression Scale for cancer patients
title_fullStr Assessment of the Hospital Anxiety and Depression Scale for cancer patients
title_full_unstemmed Assessment of the Hospital Anxiety and Depression Scale for cancer patients
title_sort assessment of the hospital anxiety and depression scale for cancer patients
publisher Sociedad Médica de Santiago
publishDate 2018
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000300300
work_keys_str_mv AT villoriaerica assessmentofthehospitalanxietyanddepressionscaleforcancerpatients
AT laralaura assessmentofthehospitalanxietyanddepressionscaleforcancerpatients
_version_ 1718436994526216192

Ejemplares similares